Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study
| Autor: | Megan, Bodge, Alexandra, Shillingburg, Stephan, Paul, Lisa, Biondo |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Adolescent Vomiting Incidence Morpholines Body Weight Remission Induction Infant Nausea Ondansetron Severity of Illness Index Dexamethasone Treatment Outcome Child Preschool Neoplasms Antineoplastic Combined Chemotherapy Protocols Antiemetics Humans Drug Therapy Combination Female Prospective Studies Child Aprepitant |
| Zdroj: | Pediatric bloodcancer. 61(6) |
| ISSN: | 1545-5017 |
| Popis: | Pediatric patients between the ages of 12 months and 17 years with a confirmed malignancy who were scheduled to receive aprepitant as part of triple therapy antiemetic prophylaxis for a cycle of moderately- or highly emetogenic chemotherapy were eligible for enrollment. Patients were evaluated for the incidence of nausea, episodes of emesis, interference with activities of daily living (ADLs), and appetite through utilization of a patient survey. Eleven patients were enrolled for a total of 20 patient encounters, mean age 9.55 ± 4.85 (range, 12 months-17 years). Aprepitant was well-tolerated and complete response (CR) rate was 38.9%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text